Medlab Clinical

Medlab Clinical EBIT

Delisted

The EBIT of Medlab Clinical (MDC.AX) as of Oct 20, 2026 is -2.26 M AUD. In the previous year, EBIT was -7.22 M AUD — a change of -68.77% (higher).

EBIT

-2.26 MAUD

YoY

-68.77%

Last updated:

In 2024, Medlab Clinical's EBIT was -2.26 M AUD, a -68.77% increase from the -7.22 M AUD EBIT recorded in the previous year.

The Medlab Clinical EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2020
-13.74 M AUD
Jan 1, 2021
-10.93 M AUD
Jan 1, 2022
-8.37 M AUD
Jan 1, 2023
-7.22 M AUD
Jan 1, 2024
-2.26 M AUD
Jan 1, 2025 (e)
-5.96 M AUD
Jan 1, 2026 (e)
-14.20 M AUD
Jan 1, 2027 (e)
0.00 AUD
The Medlab Clinical EBIT history
YEAREBITYoY
est0.00AUD-100.00%
est-14.20 MAUD+138.24%
est-5.96 MAUD+164.14%
-2.26 MAUD-68.77%
-7.22 MAUD-13.67%
-8.37 MAUD-23.42%
-10.93 MAUD-20.43%
-13.74 MAUD+63.80%
-8.39 MAUD+78.30%
-4.70 MAUD+23.06%
-3.82 MAUD+2.94%
-3.71 MAUD-4.76%
-3.90 MAUD+116.56%
-1.80 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medlab Clinical Revenue

Medlab Clinical Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
2.92 M AUD
-13.74 M AUD
-13.40 M AUD
Jan 1, 2021
757,900.00 AUD
-10.93 M AUD
-6.78 M AUD
Jan 1, 2022
1.33 M AUD
-8.37 M AUD
-7.16 M AUD
Jan 1, 2023
943,700.00 AUD
-7.22 M AUD
-6.78 M AUD
Jan 1, 2024
14,600.00 AUD
-2.26 M AUD
-2.13 M AUD
Jan 1, 2025 (e)
6.87 M AUD
-5.96 M AUD
-2.51 M AUD
Jan 1, 2026 (e)
17.90 M AUD
-14.20 M AUD
-8.05 M AUD
Jan 1, 2027 (e)
20.90 M AUD
0.00 AUD
-9.90 M AUD

Medlab Clinical Margins

Medlab Clinical stock margins

The Medlab Clinical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medlab Clinical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medlab Clinical.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
2.95 %
-469.67 %
-458.18 %
Jan 1, 2021
93.17 %
-1,442.01 %
-895.10 %
Jan 1, 2022
73.37 %
-630.59 %
-539.66 %
Jan 1, 2023
90.35 %
-765.58 %
-718.28 %
Jan 1, 2024
100.00 %
-15,452.05 %
-14,593.15 %
Jan 1, 2025 (e)
100.00 %
-86.76 %
-36.55 %
Jan 1, 2026 (e)
100.00 %
-79.33 %
-44.97 %
Jan 1, 2027 (e)
100.00 %
0.00 %
-47.37 %

Medlab Clinical Stock analysis

What does Medlab Clinical do? Medlab Clinical Ltd is an innovative biotechnology company focused on the development and commercialization of medical products and services. The company was founded in Australia in 2012 and is now based in Sydney. Since its founding, Medlab has established itself as a leading provider of diagnostic and therapeutic products. Medlab's business model consists of three different divisions. The first division is pharmaceutical development, where Medlab works on the development of new medications for the treatment of conditions such as fibromyalgia, pain, or ADHD. Medlab is particularly innovative in the development of medications based on the use of cannabinoids that are approved for medical use. The second division of Medlab is the research and development of nutritional supplements. The company works on the development of innovative products to improve general well-being and support health. An example is the nutritional supplement NRGBiotic, which contains special probiotic bacteria that help regulate the intestinal flora and thereby strengthen the immune system. The third division of Medlab is clinical diagnostics. The company offers various medical diagnostic tests, such as the test for food intolerances. This test is based on a blood sample and allows for targeted dietary changes in individuals with intolerance. Medlab aims to improve people's lives by developing and providing innovative products and services for medical care. Medlab's products are designed to promote the health and well-being of patients and customers and improve their quality of life. One outstanding product from Medlab is NanoCBD, an innovative form of cannabinoid delivery for medical purposes. The advantage of NanoCBD is that it has increased bioavailability due to the nanoparticles, resulting in faster and more effective action than conventional CBD products. Another product from Medlab is the pain medication NanaBis, which works faster and more effectively than other pain medications due to its unique formulation. Thanks to its special composition, NanaBis can also be taken by patients with severe chronic pain who do not respond to other pain medications. Medlab has established itself as a global company and is present worldwide. The company maintains partnerships and collaborations with renowned research institutions and doctors in Europe, North America, Australia, and Asia. Medlab works closely with medical professionals to ensure that the company's products and services meet the highest quality standards and meet the needs of patients and customers. Overall, Medlab Clinical Ltd has established itself as an innovative and reliable company in the medical industry. With its clear focus on the development of innovative medications, nutritional supplements, and diagnostic systems, Medlab significantly contributes to improving the healthcare system and increasing the well-being of people worldwide. Medlab Clinical is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Medlab Clinical's EBIT

Medlab Clinical's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Medlab Clinical's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Medlab Clinical's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Medlab Clinical’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Medlab Clinical stock

EBIT of Medlab Clinical is -2.26 M AUD in 2024.

EBIT of Medlab Clinical changed from -7.22 M AUD to -2.26 M AUD, representing a -68.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Medlab Clinical since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Medlab Clinical historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Medlab Clinical

All Key Metrics — Medlab Clinical